Subtype
Neck Carcinoma
CI-CAN-00003406Explore in graph →
- NCIt
- C6077
Loading cancer entity…
Subtype
CI-CAN-00003406Explore in graph →
Variants & evidence
106 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| TERT Promoter Mutation1 | ||||||||
| Iodine I-131 | Thyroid Gland Carcinoma | Predictive | B | Supports Resistance | 3 | submitted | EID6961Differentiated thyroid cancer patients with distant metastatic disease (N=66) were evaluated for radioiodine uptake and therapeutic response. Compared to patients with wildtype TERT, patients with TER… (full text at CIViC) PMID 27493271 · Yang et al., 2017 · Open in CIViC | civic |
| NTRK1 Fusion1 | ||||||||
| Larotrectinib | Thyroid Gland Papillary CarcinomaALIAS | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID8042A healthy 12 year old with right neck mass was found to have heterogeneous solid mass originating from the right thyroid lobe. Total thyroidectomy confirmed papillary thyroid carcinoma (PTC) with mult… (full text at CIViC) PMID 29610391 · Ronsley et al., 2018 · Open in CIViC | civic |
| NTRK1 Fusion1 | ||||||||
| Larotrectinib | Thyroid Gland Papillary CarcinomaALIAS | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID11747FFPE samples from 351 primary thyroid carcinomas were subjected to targeted gene rearrangement next-generation sequencing, and 11 NTRK rearrangements were found, all with intact kinase domains, and in… (full text at CIViC) PMID 32457407 · Chu et al., 2020 · Open in CIViC | civic |
| TSC2 Q1178*1 | ||||||||
| Everolimus | Thyroid Gland Carcinoma | Predictive | C | Supports Sensitivity Response | 5 | accepted | EID1108In a phase II trial of everolimus in thyroid cancer (NCT00936858), seven patients with anaplastic thyroid carcinoma were treated, and only one patient achieved an objective response. This 57-year-old … (full text at CIViC) PMID 25295501 · Wagle et al., 2014 · Open in CIViC | civic |
| ALK Fusion1 | ||||||||
| Crizotinib | Thyroid Gland Anaplastic CarcinomaALIAS | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID5954A patient with anaplastic thyroid carcinoma harboring ALK rearrangement received crizotinib after chemotherapy for pulmonary recurrence. Crizotinib showed confirmed response of more than 90% by tumor … (full text at CIViC) PMID 24687827 · Godbert et al., 2015 · Open in CIViC | civic |
| RET Fusion1 | ||||||||
| Selpercatinib | Thyroid Gland Papillary CarcinomaALIAS | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID7069In this phase 1 trial, patients with RET-fusion or mutation positive cancers were treated with the selective RET-inhibitor selpercatinib (LOXO-292). Among the 6 patients with RET-fusion positive papil… (full text at CIViC) | civic |
Data updated 15 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.